Post
Pharma industry groups push initiatives against climate change at COP28
Several pharmaceutical industry advocacy and lobby organisations have bandied together to release a joint industry statement supporting the Declaration on …
Capmatinib hydrochloride by Novartis for Metastatic Melanoma: Likelihood of Approval
Capmatinib hydrochloride is under clinical development by Novartis and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase …
Cabiralizumab by Bristol-Myers Squibb for Melanoma: Likelihood of Approval
Cabiralizumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Melanoma. According to GlobalData, Phase I …
BMS-986360 by Bristol-Myers Squibb for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
BMS-986360 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to …
FPI-2059 by Fusion Pharmaceuticals for Metastatic Colorectal Cancer: Likelihood of Approval
FPI-2059 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, …
Pidnarulex by Senhwa Biosciences for Solid Tumor: Likelihood of Approval
Pidnarulex is under clinical development by Senhwa Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase …
Everest inches towards clinical studies for renal disease drug in China
Everest Medicines is on track to commence clinical trials in China for its renal disease drug candidate, following the acceptance …
AGI-134 by BioLineRx for Solid Tumor: Likelihood of Approval
AGI-134 is under clinical development by BioLineRx and currently in Phase II for Solid Tumor. According to GlobalData, Phase II …
Gepotidacin mesylate by GSK for Cystitis: Likelihood of Approval
Gepotidacin mesylate is under clinical development by GSK and currently in Phase III for Cystitis. According to GlobalData, Phase III …
AGI-134 by BioLineRx for Breast Cancer: Likelihood of Approval
AGI-134 is under clinical development by BioLineRx and currently in Phase II for Breast Cancer. According to GlobalData, Phase II …
Deferiprone by Chiesi Farmaceutici for Parkinson’s Disease: Likelihood of Approval
Deferiprone is under clinical development by Chiesi Farmaceutici and currently in Phase II for Parkinson's Disease. According to GlobalData, Phase …
Gallium Maltolate by Titan Pharmaceuticals for Glioblastoma Multiforme (GBM): Likelihood of Approval
Gallium Maltolate is under clinical development by Titan Pharmaceuticals and currently in Phase I for Glioblastoma Multiforme (GBM). According to …
AGI-134 by BioLineRx for Metastatic Colorectal Cancer: Likelihood of Approval
AGI-134 is under clinical development by BioLineRx and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase …
Pitolisant hydrochloride by Harmony Biosciences for Prader-Willi Syndrome (PWS): Likelihood of Approval
Pitolisant hydrochloride is under clinical development by Harmony Biosciences and currently in Phase II for Prader-Willi Syndrome (PWS). According to …
Ruxolitinib phosphate by Incyte for Hidradenitis Suppurativa: Likelihood of Approval
Ruxolitinib phosphate is under clinical development by Incyte and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase …